Ryanodine receptors: Physiological function and deregulation in Alzheimer disease

Molecular Neurodegeneration

Volumn 9, Issue 1, 2014, Pages

  Del Prete, Dolores ^a,b,c   Checler, Frédéric ^a,b   Chami, Mounia ^a,b  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer disease; Amyloid beta; Amyloid precursor protein; Calcium; Endoplasmic reticulum; Neurodegeneration; Presenilin; Ryanodine receptor

Indexed keywords

AMYLOID BETA PROTEIN; CALCIUM; PRESENILIN; RYANODINE RECEPTOR;

ALZHEIMER DISEASE; AMNESIA; CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; DRUG TARGETING; GENETIC MANIPULATION; HUMAN; LEARNING DISORDER; MEMORY; MINIATURE ENDPLATE POTENTIAL; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROTRANSMITTER RELEASE; NONHUMAN; PHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; ANIMALS; HUMANS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 84903209626     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-9-21     Document Type: Review

References (175)

1. Neuropsychology of cognitive ageing, minimal cognitive impairment, Alzheimer's disease, and vascular cognitive impairment. Lindeboom J, Weinstein H, Eur J Pharmacol 2004 490 83 86 10.1016/j.ejphar.2004.02.046 15094075 (Pubitemid 38482162)
2. Processing of the beta-amyloid precursor protein and its regulation in Alzheimer's disease. Checler F, J Neurochem 1995 65 1431 1444 7561836
3. Processive proteolysis by gamma-secretase and the mechanism of Alzheimer's disease. Wolfe MS, Biol Chem 2012 393 899 905 22944690
4. Tau pathology: a marker of neurodegenerative disorders. Delacourte A, Buee L, Curr Opin Neurol 2000 13 371 376 10.1097/00019052-200008000-00002 10970052
5. Molecular genetics of familial Alzheimer's disease. St George-Hyslop PH, Tanzi RE, Haines JL, Polinsky RJ, Farrer L, Myers RH, Gusella JF, Eur Neurol 1989 29 Suppl 3 25 27 2693103 (Pubitemid 20011220)
6. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Tanzi RE, Bertram L, Cell 2005 120 545 555 10.1016/j.cell.2005.02. 008 15734686 (Pubitemid 40269768)
7. APP processing in Alzheimer's disease. Zhang YW, Thompson R, Zhang H, Xu H, Mol Brain 2011 4 3 10.1186/1756-6606-4-3 21214928
8. Production of amyloid beta protein from normal amyloid beta-protein precursor (beta APP) and the mutated beta APPS linked to familial Alzheimer's disease. Golde TE, Cai XD, Shoji M, Younkin SG, Ann N Y Acad Sci 1993 695 103 108 10.1111/j.1749-6632.1993.tb23036.x 8239266 (Pubitemid 23348245)
9. When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. talking point on the role of presenilin mutations in Alzheimer disease. Wolfe MS, EMBO Rep 2007 8 136 140 10.1038/sj.embor.7400896 17268504 (Pubitemid 46420840)
10. Calcium signalling: dynamics, homeostasis and remodelling. Berridge MJ, Bootman MD, Roderick HL, Nat Rev Mol Cell Biol 2003 4 517 529 10.1038/nrm1155 12838335 (Pubitemid 36773404)
11. Calcium-a life and death signal. Berridge MJ, Bootman MD, Lipp P, Nature 1998 395 645 648 10.1038/27094 9790183 (Pubitemid 28475949)
12. The endoplasmic reticulum Ca2+ store: a view from the lumen. Meldolesi J, Pozzan T, Trends Biochem Sci 1998 23 10 14 10.1016/S0968-0004(97)01143-2 9478128 (Pubitemid 28093986)
13. Dynamics of the endoplasmic reticulum and other membranous organelles in growth cones of cultured neurons. Dailey ME, Bridgman PC, J Neurosci 1989 9 1897 1909 2723756 (Pubitemid 19156978)
14. The endoplasmic reticulum: a multifunctional signaling organelle. Berridge MJ, Cell Calcium 2002 32 235 249 10.1016/S0143416002001823 12543086 (Pubitemid 36175747)
15. Differential distribution of endoplasmic reticulum controls metabotropic signaling and plasticity at hippocampal synapses. Holbro N, Grunditz A, Oertner TG, Proc Natl Acad Sci U S A 2009 106 15055 15060 10.1073/pnas.0905110106 19706463
16. Calcium stores in hippocampal synaptic boutons mediate short-term plasticity, store-operated Ca2+ entry, and spontaneous transmitter release. Emptage NJ, Reid CA, Fine A, Neuron 2001 29 197 208 10.1016/S0896-6273(01)00190- 8 11182091 (Pubitemid 32108732)
17. Cell-permeant caged InsP3 ester shows that Ca2+ spike frequency can optimize gene expression. Li W, Llopis J, Whitney M, Zlokarnik G, Tsien RY, Nature 1998 392 936 941 10.1038/31965 9582076 (Pubitemid 28232067)
18. Role of intracellular calcium in NI-35-evoked collapse of neuronal growth cones. Bandtlow CE, Schmidt MF, Hassinger TD, Schwab ME, Kater SB, Science 1993 259 80 83 10.1126/science.8418499 8418499 (Pubitemid 23036090)
19. Calcium, membranes, aging, and Alzheimer's disease. introduction and overview. Khachaturian ZS, Ann N Y Acad Sci 1989 568 1 4 10.1111/j.1749-6632. 1989.tb12485.x (Pubitemid 20166513)
20. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Bezprozvanny I, Mattson MP, Trends Neurosci 2008 31 454 463 10.1016/j.tins.2008.06.005 18675468
21. The dysregulation of intracellular calcium in Alzheimer disease. Supnet C, Bezprozvanny I, Cell Calcium 2010 47 183 189 10.1016/j.ceca.2009.12.014 20080301
22. Calcium channelopathies and Alzheimer's disease: insight into therapeutic success and failures. Chakroborty S, Stutzmann GE, Eur J Pharmacol 2013 pii: S0014-2999 13 00883-2 doi:10.1016/j.ejphar.2013.11.012. [Epub ahead of print]. PMID: 24316360
23. Can the calcium hypothesis explain synaptic loss in Alzheimer's disease? Popugaeva E, Bezprozvanny I, Neurodegener Dis 2014 13 139 141 10.1159/000354778 24080896
24. ER calcium and Alzheimer's disease: in a state of flux. Mattson MP, Sci Signal 2010 3 e10 20332425
25. Endoplasmic reticulum Ca(2+) handling in excitable cells in health and disease. Stutzmann GE, Mattson MP, Pharmacol Rev 2011 63 700 727 10.1124/pr.110.003814 21737534
26. The ryanodine receptor/calcium channel genes are widely and differentially expressed in murine brain and peripheral tissues. Giannini G, Conti A, Mammarella S, Scrobogna M, Sorrentino V, J Cell Biol 1995 128 893 904 10.1083/jcb.128.5.893 7876312
27. Modulation of the ryanodine receptor and intracellular calcium. Zalk R, Lehnart SE, Marks AR, Annu Rev Biochem 2007 76 367 385 10.1146/annurev.biochem. 76.053105.094237 17506640
28. Characterization of type 3 ryanodine receptor (RyR3) of sarcoplasmic reticulum from rabbit skeletal muscles. Murayama T, Ogawa Y, J Biol Chem 1997 272 24030 24037 10.1074/jbc.272.38.24030 9295356 (Pubitemid 27410988)
29. Single-channel properties of the recombinant skeletal muscle Ca2+ release channel (ryanodine receptor). Chen SR, Leong P, Imredy JP, Bartlett C, Zhang L, MacLennan DH, Biophys J 1997 73 1904 1912 10.1016/S0006-3495(97)78221-3 9336186 (Pubitemid 27425721)
30. Caffeine-induced calcium release from internal stores in cultured rat sensory neurons. Usachev Y, Shmigol A, Pronchuk N, Kostyuk P, Verkhratsky A, Neuroscience 1993 57 845 859 10.1016/0306-4522(93)90029-F 8309540 (Pubitemid 23350570)
31. Fast confocal imaging of calcium released from stores in dendritic spines. Korkotian E, Segal M, Eur J Neurosci 1998 10 2076 2084 10.1046/j.1460-9568.1998.00219.x 9753094 (Pubitemid 28327355)
32. Ryanodine activation and inhibition of the Ca2+ release channel of sarcoplasmic reticulum. Meissner G, J Biol Chem 1986 261 6300 6306 2422165 (Pubitemid 17204136)
33. Magnesium inhibition of ryanodine-receptor calcium channels: evidence for two independent mechanisms. Laver DR, Baynes TM, Dulhunty AF, J Membr Biol 1997 156 213 229 10.1007/s002329900202 9096063 (Pubitemid 27208424)
34. Reduced inhibitory effect of Mg2+ on ryanodine receptor-Ca2+ release channels in malignant hyperthermia. Laver DR, Owen VJ, Junankar PR, Taske NL, Dulhunty AF, Lamb GD, Biophys J 1997 73 1913 1924 10.1016/S0006-3495(97)78222-5 9336187 (Pubitemid 27425722)
35. 1-[(5-arylfurfurylidene)amino]hydantoins. a new class of muscle relaxants. Snyder HR Jr, Davis CS, Bickerton RK, Halliday RP, J Med Chem 1967 10 807 810 10.1021/jm00317a011 6048486
36. Dantrolene in human malignant hyperthermia. Kolb ME, Horne ML, Martz R, Anesthesiology 1982 56 254 262 10.1097/00000542-198204000-00005 7039419
37. Dantrolene inhibition of sarcoplasmic reticulum Ca2+ release by direct and specific action at skeletal muscle ryanodine receptors. Fruen BR, Mickelson JR, Louis CF, J Biol Chem 1997 272 26965 26971 10.1074/jbc.272.43.26965 9341133 (Pubitemid 27452649)
38. Dantrolene inhibition of ryanodine receptor Ca2+ release channels. molecular mechanism and isoform selectivity. Zhao F, Li P, Chen SR, Louis CF, Fruen BR, J Biol Chem 2001 276 13810 13816 11278295
39. Probing a putative dantrolene-binding site on the cardiac ryanodine receptor. Paul-Pletzer K, Yamamoto T, Ikemoto N, Jimenez LS, Morimoto H, Williams PG, Ma J, Parness J, Biochem J 2005 387 905 909 10.1042/BJ20041336 15656791 (Pubitemid 40685728)
40. Localization of the dantrolene-binding sequence near the FK506-binding protein-binding site in the three-dimensional structure of the ryanodine receptor. Wang R, Zhong X, Meng X, Koop A, Tian X, Jones PP, Fruen BR, Wagenknecht T, Liu Z, Chen SR, J Biol Chem 2011 286 12202 12212 10.1074/jbc.M110.194316 21262961
41. Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. Kobayashi S, Yano M, Suetomi T, Ono M, Tateishi H, Mochizuki M, Xu X, Uchinoumi H, Okuda S, Yamamoto T, Koseki N, Kyushiki H, Ikemoto N, Matsuzaki M, J Am Coll Cardiol 2009 53 1993 2005 10.1016/j.jacc.2009.01.065 19460614
42. Dantrolene prevents arrhythmogenic Ca2+ release in heart failure. Maxwell JT, Domeier TL, Blatter LA, Am J Physiol Heart Circ Physiol 2012 302 953 H963 10.1152/ajpheart.00936.2011 22180651
43. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. Jung CB, Moretti A, Mederos y Schnitzler M, Iop L, Storch U, Bellin M, Dorn T, Ruppenthal S, Pfeiffer S, Goedel A, Dirschinger RJ, Seyfarth M, Lam JT, Sinnecker D, Gudermann T, Lipp P, Laugwitz KL, EMBO Mol Med 2012 4 180 191 10.1002/emmm.201100194 22174035
44. Azumolene inhibits a component of store-operated calcium entry coupled to the skeletal muscle ryanodine receptor. Zhao X, Weisleder N, Han X, Pan Z, Parness J, Brotto M, Ma J, J Biol Chem 2006 281 33477 33486 10.1074/jbc. M602306200 16945924 (Pubitemid 46036729)
45. Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Lanner JT, Georgiou DK, Joshi AD, Hamilton SL, Cold Spring Harb Perspect Biol 2010 2 003996 20961976
46. Modulation of intracellular calcium-release channels by calmodulin. Balshaw DM, Yamaguchi N, Meissner G, J Membr Biol 2002 185 1 8 10.1007/s00232-001-0111-4 11891559 (Pubitemid 34074999)
47. FK506 binding proteins: cellular regulators of intracellular Ca2+ signalling. MacMillan D, Eur J Pharmacol 2013 700 181 193 10.1016/j.ejphar.2012. 12.029 23305836
48. Cardiac ryanodine receptor phosphorylation by CaM Kinase II: keeping the balance right. Currie S, Front Biosci (Landmark Ed) 2009 14 5134 5156 10.2741/3591 19482609
49. Modulation of intracellular Ca2+ levels in the heart by sorcin and FKBP12, two accessory proteins of ryanodine receptors. Valdivia HH, Trends Pharmacol Sci 1998 19 479 482 10.1016/S0165-6147(98)01269-3 9871407 (Pubitemid 29008533)
50. Complex formation between junctin, triadin, calsequestrin, and the ryanodine receptor. Proteins of the cardiac junctional sarcoplasmic reticulum membrane. Zhang L, Kelley J, Schmeisser G, Kobayashi YM, Jones LR, J Biol Chem 1997 272 23389 23397 10.1074/jbc.272.37.23389 9287354 (Pubitemid 27392481)
51. Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Andersson DC, Betzenhauser MJ, Reiken S, Meli AC, Umanskaya A, Xie W, Shiomi T, Zalk R, Lacampagne A, Marks AR, Cell Metab 2011 14 196 207 10.1016/j.cmet.2011.05.014 21803290
52. Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Bellinger AM, Reiken S, Carlson C, Mongillo M, Liu X, Rothman L, Matecki S, Lacampagne A, Marks AR, Nat Med 2009 15 325 330 10.1038/nm.1916 19198614
53. Remodeling of ryanodine receptor complex causes "leaky" channels: a molecular mechanism for decreased exercise capacity. Bellinger AM, Reiken S, Dura M, Murphy PW, Deng SX, Landry DW, Nieman D, Lehnart SE, Samaru M, LaCampagne A, Marks AR, Proc Natl Acad Sci U S A 2008 105 2198 2202 10.1073/pnas.0711074105 18268335 (Pubitemid 351439488)
54. Ryanodine receptor leak mediated by caspase-8 activation leads to left ventricular injury after myocardial ischemia-reperfusion. Fauconnier J, Meli AC, Thireau J, Roberge S, Shan J, Sassi Y, Reiken SR, Rauzier JM, Marchand A, Chauvier D, Cassan C, Crozier C, Bideaux P, Lompré AM, Jacotot E, Marks AR, Lacampagne A, Proc Natl Acad Sci U S A 2011 108 13258 13263 10.1073/pnas.1100286108 21788490
55. Role of leaky neuronal ryanodine receptors in stress-induced cognitive dysfunction. Liu X, Betzenhauser MJ, Reiken S, Meli AC, Xie W, Chen BX, Arancio O, Marks AR, Cell 2012 150 1055 1067 10.1016/j.cell.2012.06.052 22939628
56. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacskai BJ, Neuron 2008 59 214 225 10.1016/j.neuron.2008.06.008 18667150 (Pubitemid 352033686)
57. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, Staufenbiel M, Konnerth A, Garaschuk O, Science 2008 321 1686 1689 10.1126/science.1162844 18802001
58. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG, J Biol Chem 2005 280 17294 17300 10.1074/jbc.M500997200 15722360 (Pubitemid 41389198)
59. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE, J Neurosci 1992 12 376 389 1346802
60. Early and late cytotoxic effects of external application of the Alzheimer's Abeta result from the initial formation and function of Abeta ion channels. Simakova O, Arispe NJ, Biochemistry 2006 45 5907 5915 10.1021/bi060148g 16669633
61. The cell-selective neurotoxicity of the Alzheimer's Abeta peptide is determined by surface phosphatidylserine and cytosolic ATP levels. membrane binding is required for Abeta toxicity. Simakova O, Arispe NJ, J Neurosci 2007 27 13719 13729 10.1523/JNEUROSCI.3006-07.2007 18077683 (Pubitemid 350278273)
62. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Arispe N, Rojas E, Pollard HB, Proc Natl Acad Sci U S A 1993 90 567 571 10.1073/pnas.90.2.567 8380642 (Pubitemid 23028904)
63. Involvement of endoplasmic reticulum Ca2+ release through ryanodine and inositol 1,4,5-triphosphate receptors in the neurotoxic effects induced by the amyloid-beta peptide. Ferreiro E, Oliveira CR, Pereira C, J Neurosci Res 2004 76 872 880 10.1002/jnr.20135 15160398 (Pubitemid 38720693)
64. Effect of amyloid beta on capacitive calcium entry in neural 2a cells. Niu Y, Su Z, Zhao C, Song B, Zhang X, Zhao N, Shen X, Gong Y, Brain Res Bull 2009 78 152 157 10.1016/j.brainresbull.2008.10.003 19000747
65. Cytotoxicity of intracellular abeta42 amyloid oligomers involves Ca2+ release from the endoplasmic reticulum by stimulated production of inositol trisphosphate. Demuro A, Parker I, J Neurosci 2013 33 3824 3833 10.1523/JNEUROSCI.4367-12.2013 23447594
66. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, Triller A, Neuron 2010 66 739 754 10.1016/j.neuron.2010.04.029 20547131
67. Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP(3) receptor channel gating. Cheung KH, Shineman D, Muller M, Cardenas C, Mei L, Yang J, Tomita T, Iwatsubo T, Lee VM, Foskett JK, Neuron 2008 58 871 883 10.1016/j.neuron.2008.04.015 18579078 (Pubitemid 351842747)
68. Internal Ca2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Ito E, Oka K, Etcheberrigaray R, Nelson TJ, McPhie DL, Tofel-Grehl B, Gibson GE, Alkon DL, Proc Natl Acad Sci U S A 1994 91 534 538 10.1073/pnas.91.2.534 8290560
69. Calcium responses in fibroblasts from asymptomatic members of Alzheimer's disease families. Etcheberrigaray R, Hirashima N, Nee L, Prince J, Govoni S, Racchi M, Tanzi RE, Alkon DL, Neurobiol Dis 1998 5 37 45 10.1006/nbdi.1998.0176 9702786 (Pubitemid 28361650)
70. Presenilin-2 mutations modulate amplitude and kinetics of inositol 1, 4,5-trisphosphate-mediated calcium signals. Leissring MA, Parker I, LaFerla FM, J Biol Chem 1999 274 32535 32538 10.1074/jbc.274.46.32535 10551803 (Pubitemid 129535275)
71. Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. Stutzmann GE, Caccamo A, LaFerla FM, Parker I, J Neurosci 2004 24 508 513 10.1523/JNEUROSCI.4386-03.2004 14724250 (Pubitemid 38112383)
72. Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice. Stutzmann GE, Smith I, Caccamo A, Oddo S, Laferla FM, Parker I, J Neurosci 2006 26 5180 5189 10.1523/JNEUROSCI.0739-06.2006 16687509 (Pubitemid 44315299)
73. SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. Green KN, Demuro A, Akbari Y, Hitt BD, Smith IF, Parker I, LaFerla FM, J Cell Biol 2008 181 1107 1116 10.1083/jcb.200706171 18591429 (Pubitemid 351915486)
74. Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. Tu H, Nelson O, Bezprozvanny A, Wang Z, Lee SF, Hao YH, Serneels L, De Strooper B, Yu G, Bezprozvanny I, Cell 2006 126 981 993 10.1016/j.cell.2006.06.059 16959576 (Pubitemid 44310781)
75. Presenilin-2 dampens intracellular Ca2+ stores by increasing Ca2+ leakage and reducing Ca2+ uptake. Brunello L, Zampese E, Florean C, Pozzan T, Pizzo P, Fasolato C, J Cell Mol Med 2009 13 3358 3369 10.1111/j.1582-4934.2009.00755.x 19382908
76. Familial Alzheimer's disease mutations in presenilins: effects on endoplasmic reticulum calcium homeostasis and correlation with clinical phenotypes. Nelson O, Supnet C, Liu H, Bezprozvanny I, J Alzheimers Dis 2010 21 781 793 20634584
77. Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1. Nelson O, Tu H, Lei T, Bentahir M, de Strooper B, Bezprozvanny I, J Clin Invest 2007 117 1230 1239 10.1172/JCI30447 17431506 (Pubitemid 46718411)
78. Role of presenilins in neuronal calcium homeostasis. Zhang H, Sun S, Herreman A, De Strooper B, Bezprozvanny I, J Neurosci 2010 30 8566 8580 10.1523/JNEUROSCI.1554-10.2010 20573903
79. Mutagenesis mapping of the presenilin 1 calcium leak conductance pore. Nelson O, Supnet C, Tolia A, Horre K, De Strooper B, Bezprozvanny I, J Biol Chem 2011 286 22339 22347 10.1074/jbc.M111.243063 21531718
80. Lack of evidence for presenilins as endoplasmic reticulum Ca2+ leak channels. Shilling D, Mak DO, Kang DE, Foskett JK, J Biol Chem 2012 287 14 10933 10944 10.1074/jbc.M111.300491 22311977
81. Response to Shilling et al. Bezprozvanny I, Supnet C, Sun S, Zhang H, De Strooper B, J Biol Chem 2012 287 20469 10.1074/jbc.M111.300491. author reply 20470 10.1074/jbc.L112.356790 22685228
82. Repression of transcription of presenilin-1 inhibits gamma-secretase independent ER Ca(2)(+) leak that is impaired by FAD mutations. Das HK, Tchedre K, Mueller B, J Neurochem 2012 122 487 500 10.1111/j.1471-4159.2012.07794.x 22607268
83. Regulators of calcium homeostasis identified by inference of kinetic model parameters from live single cells perturbed by siRNA. Bandara S, Malmersjo S, Meyer T, Sci Signal 2013 6 a56 23838183
84. Activation of K + channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein. Furukawa K, Barger SW, Blalock EM, Mattson MP, Nature 1996 379 74 78 10.1038/379074a0 8538744 (Pubitemid 26008138)
85. A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Cao X, Sudhof TC, Science 2001 293 115 120 10.1126/science.1058783 11441186 (Pubitemid 32625507)
86. A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Leissring MA, Murphy MP, Mead TR, Akbari Y, Sugarman MC, Jannatipour M, Anliker B, Müller U, Saftig P, De Strooper B, Wolfe MS, Golde TE, LaFerla FM, Proc Natl Acad Sci U S A 2002 99 4697 4702 10.1073/pnas.072033799 11917117 (Pubitemid 34286047)
87. The physiology of the beta-amyloid precursor protein intracellular domain AICD. Pardossi-Piquard R, Checler F, J Neurochem 2012 120 Suppl 1 109 124 22122663
88. AICD Overexpression in neuro 2A cells regulates expression of PTCH1 and TRPC5. Raychaudhuri M, Mukhopadhyay D, Int J Alzheimers Dis 2011 ii: 239453 doi:10.4061/2011/239453
89. Downregulation of AbetaPP enhances both calcium content of endoplasmic reticulum and acidic stores and the dynamics of store operated calcium channel activity. Chatzistavraki M, Kyratzi E, Fotinopoulou A, Papazafiri P, Efthimiopoulos S, J Alzheimers Dis 2013 34 407 415 23241555
90. Abnormalities in Alzheimer's disease fibroblasts bearing the APP670/671 mutation. Gibson GE, Vestling M, Zhang H, Szolosi S, Alkon D, Lannfelt L, Gandy S, Cowburn RF, Neurobiol Aging 1997 18 573 580 10.1016/S0197-4580(97)00149-8 9461055 (Pubitemid 28046410)
91. Amyloid-beta-(1-42) increases ryanodine receptor-3 expression and function in neurons of TgCRND8 mice. Supnet C, Grant J, Kong H, Westaway D, Mayne M, J Biol Chem 2006 281 38440 38447 10.1074/jbc.M606736200 17050533 (Pubitemid 46041967)
92. Ryanodine receptor blockade reduces amyloid-beta load and memory impairments in Tg2576 mouse model of Alzheimer disease. Oulès B, Del Prete D, Greco B, Zhang X, Lauritzen I, Sevalle J, Moreno S, Paterlini-Bréchot P, Trebak M, Checler F, Benfenati F, Chami M, J Neurosci 2012 32 11820 11834 10.1523/JNEUROSCI.0875-12.2012 22915123
93. Gamma-secretase activity of presenilin 1 regulates acetylcholine muscarinic receptor-mediated signal transduction. Popescu BO, Cedazo-Minguez A, Benedikz E, Nishimura T, Winblad B, Ankarcrona M, Cowburn RF, J Biol Chem 2004 279 6455 6464 14625299 (Pubitemid 38248779)
94. Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer's disease. Smith IF, Hitt B, Green KN, Oddo S, LaFerla FM, J Neurochem 2005 94 1711 1718 10.1111/j.1471-4159.2005.03332.x 16156741 (Pubitemid 41324651)
95. Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. Chan SL, Mayne M, Holden CP, Geiger JD, Mattson MP, J Biol Chem 2000 275 18195 18200 10.1074/jbc.M000040200 10764737 (Pubitemid 30414771)
96. PS2 mutation increases neuronal cell vulnerability to neurotoxicants through activation of caspase-3 by enhancing of ryanodine receptor-mediated calcium release. Lee SY, Hwang DY, Kim YK, Lee JW, Shin IC, Oh KW, Lee MK, Lim JS, Yoon DY, Hwang SJ, Hong JT, FASEB J 2006 20 151 153 10.1096/fj.05-4017fje;1 16394273 (Pubitemid 43100497)
97. Presenilins regulate calcium homeostasis and presynaptic function via ryanodine receptors in hippocampal neurons. Wu B, Yamaguchi H, Lai FA, Shen J, Proc Natl Acad Sci U S A 2013 110 15091 15096 10.1073/pnas.1304171110 23918386
98. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ III, Kandel ER, Duff K, Kirkwood A, Shen J, Neuron 2004 42 23 36 10.1016/S0896-6273(04)00182-5 15066262 (Pubitemid 38456965)
99. Presenilins are essential for regulating neurotransmitter release. Zhang C, Wu B, Beglopoulos V, Wines-Samuelson M, Zhang D, Dragatsis I, Sudhof TC, Shen J, Nature 2009 460 632 636 10.1038/nature08177 19641596
100. Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic 3xTg-AD mice. Chakroborty S, Goussakov I, Miller MB, Stutzmann GE, J Neurosci 2009 29 9458 9470 10.1523/JNEUROSCI.2047-09.2009 19641109
101. Ca2+ dysregulation in neurons from transgenic mice expressing mutant presenilin 2. Kipanyula MJ, Contreras L, Zampese E, Lazzari C, Wong AK, Pizzo P, Fasolato C, Pozzan T, Aging Cell 2012 11 885 893 10.1111/j.1474-9726.2012. 00858.x 22805202
102. NMDA-mediated Ca(2+) influx drives aberrant ryanodine receptor activation in dendrites of young Alzheimer's disease mice. Goussakov I, Miller MB, Stutzmann GE, J Neurosci 2010 30 12128 12137 10.1523/JNEUROSCI.2474-10.2010 20826675
103. Increased intraneuronal resting [Ca(2+)] in adult Alzheimer's disease mice. Lopez JR, Lyckman A, Oddo S, Laferla FM, Querfurth HW, Shtifman A, J Neurochem 2008 105 1 262 271 10.1111/j.1471-4159.2007.05135.x 18021291 (Pubitemid 351441642)
104. Effect of the knockdown of amyloid precursor protein on intracellular calcium increases in a neuronal cell line derived from the cerebral cortex of a trisomy 16 mouse. Rojas G, Cardenas AM, Fernandez-Olivares P, Shimahara T, Segura-Aguilar J, Caviedes R, Caviedes P, Exp Neurol 2008 209 234 242 10.1016/j.expneurol.2007.09.024 17976585
105. Amyloid beta-peptide oligomers, ryanodine receptor-mediated Ca(2+) release, and Wnt-5a/Ca(2+) signaling: opposing roles in neuronal mitochondrial dynamics? Paula-Lima AC, Hidalgo C, Front Cell Neurosci 2013 7 120 23908603
106. Amyloid-beta protein impairs Ca2+ release and contractility in skeletal muscle. Shtifman A, Ward CW, Laver DR, Bannister ML, Lopez JR, Kitazawa M, LaFerla FM, Ikemoto N, Querfurth HW, Neurobiol Aging 2010 31 2080 2090 10.1016/j.neurobiolaging.2008.11.003 19108934
107. Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillary and beta-amyloid pathologies. Kelliher M, Fastbom J, Cowburn RF, Bonkale W, Ohm TG, Ravid R, Sorrentino V, O'Neill C, Neuroscience 1999 92 499 513 10.1016/S0306-4522(99)00042-1 10408600 (Pubitemid 29268039)
108. Altered ryanodine receptor expression in mild cognitive impairment and Alzheimer's disease. Bruno AM, Huang JY, Bennett DA, Marr RA, Hastings ML, Stutzmann GE, Neurobiol Aging 2012 33 1001 1006
109. A preliminary study of the whole-genome expression profile of sporadic and monogenic early-onset Alzheimer's disease. Antonell A, Lladó A, Altirriba J, Botta-Orfila T, Balasa M, Fernández M, Ferrer I, Sánchez-Valle R, Molinuevo JL, Neurobiol Aging 2013 34 1772 1778 10.1016/j.neurobiolaging.2012.12.026 23369545
110. Enhanced ryanodine-mediated calcium release in mutant PS1-expressing Alzheimer's mouse models. Stutzmann GE, Smith I, Caccamo A, Oddo S, Parker I, Laferla F, Ann N Y Acad Sci 2007 1097 265 277 10.1196/annals.1379.025 17413028 (Pubitemid 47084900)
111. The role of ryanodine receptor type 3 in a mouse model of Alzheimer disease. Liu J, Supnet C, Sun S, Zhang H, Good L, Popugaeva E, Bezprozvanny I, Channels (Austin) 2014 8 3 [Epub ahead of print]
112. Amyloid beta-peptide oligomers stimulate RyR-mediated Ca2+ release inducing mitochondrial fragmentation in hippocampal neurons and prevent RyR-mediated dendritic spine remodeling produced by BDNF. Paula-Lima AC, Adasme T, SanMartin C, Sebollela A, Hetz C, Carrasco MA, Ferreira ST, Hidalgo C, Antioxid Redox Signal 2011 14 1209 1223 10.1089/ars.2010.3287 20712397
113. BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and beta-amyloid production in Alzheimer's disease. Chami L, Checler F, Mol Neurodegener 2012 7 52 10.1186/1750-1326-7-52 23039869
114. The ER stress factor XBP1s prevents amyloid-beta neurotoxicity. Casas-Tinto S, Zhang Y, Sanchez-Garcia J, Gomez-Velazquez M, Rincon-Limas DE, Fernandez-Funez P, Hum Mol Genet 2011 20 2144 2160 10.1093/hmg/ddr100 21389082
115. Presenilin 2 regulates the systolic function of heart by modulating Ca2+ signaling. Takeda T, Asahi M, Yamaguchi O, Hikoso S, Nakayama H, Kusakari Y, Kawai M, Hongo K, Higuchi Y, Kashiwase K, Watanabe T, Taniike M, Nakai A, Nishida K, Kurihara S, Donoviel DB, Bernstein A, Tomita T, Iwatsubo T, Hori M, Otsu K, FASEB J 2005 19 2069 2071 16204356 (Pubitemid 41759768)
116. The N-terminus of presenilin-2 increases single channel activity of brain ryanodine receptors through direct protein-protein interaction. Hayrapetyan V, Rybalchenko V, Rybalchenko N, Koulen P, Cell Calcium 2008 44 507 518 10.1016/j.ceca.2008.03.004 18440065
117. The cytosolic N-terminus of presenilin-1 potentiates mouse ryanodine receptor single channel activity. Rybalchenko V, Hwang SY, Rybalchenko N, Koulen P, Int J Biochem Cell Biol 2008 40 84 97 10.1016/j.biocel.2007.06.023 17709274 (Pubitemid 350052661)
118. Presenilin 2 interacts with sorcin, a modulator of the ryanodine receptor. Pack-Chung E, Meyers MB, Pettingell WP, Moir RD, Brownawell AM, Cheng I, Tanzi RE, Kim TW, J Biol Chem 2000 275 14440 14445 10.1074/jbc.M909882199 10748169 (Pubitemid 30339730)
119. Ischemia enhances activation by Ca2+ and redox modification of ryanodine receptor channels from rat brain cortex. Bull R, Finkelstein JP, Galvez J, Sanchez G, Donoso P, Behrens MI, Hidalgo C, J Neurosci 2008 28 9463 9472 10.1523/JNEUROSCI.2286-08.2008 18799678
120. Disrupting function of FK506-binding protein 1b/12.6 induces the Ca(2) + -dysregulation aging phenotype in hippocampal neurons. Gant JC, Chen KC, Norris CM, Kadish I, Thibault O, Blalock EM, Porter NM, Landfield PW, J Neurosci 2011 31 1693 1703 10.1523/JNEUROSCI.4805-10.2011 21289178
121. Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. Barnham KJ, Haeffner F, Ciccotosto GD, Curtain CC, Tew D, Mavros C, Beyreuther K, Carrington D, Masters CL, Cherny RA, Cappai R, Bush AI, FASEB J 2004 18 1427 1429 15231727 (Pubitemid 39561603)
122. Neurodegenerative diseases and oxidative stress. Emerit J, Edeas M, Bricaire F, Biomed Pharmacother 2004 58 39 46 14739060 (Pubitemid 38117047)
123. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Lin MT, Beal MF, Nature 2006 443 787 795 10.1038/nature05292 17051205 (Pubitemid 44622683)
124. Inhibition of Abeta production and APP maturation by a specific PKA inhibitor. Su Y, Ryder J, Ni B, FEBS Lett 2003 546 407 410 10.1016/S0014- 5793(03)00645-8 12832078 (Pubitemid 36782448)
125. Post-transcriptional contribution of a cAMP-dependent pathway to the formation of alpha- and beta/gamma-secretases-derived products of beta APP maturation in human cells expressing wild-type and Swedish mutated beta APP. Marambaud P, Chevallier N, Ancolio K, Checler F, Mol Med 1998 4 715 723 9932109 (Pubitemid 29051377)
126. Effect of protein kinase A inhibitors on the production of Abeta40 and Abeta42 by human cells expressing normal and Alzheimer's disease-linked mutated betaAPP and presenilin 1. Marambaud P, Ancolio K, Alves da Costa C, Checler F, Br J Pharmacol 1999 126 1186 1190 10.1038/sj.bjp.0702406 10205007 (Pubitemid 29123754)
127. Protein kinase inhibitor attenuates apoptotic cell death induced by amyloid beta protein in culture of the rat cerebral cortex. Ueda K, Yagami T, Kageyama H, Kawasaki K, Neurosci Lett 1996 203 175 178 10.1016/0304-3940(95) 12288-5 8742021 (Pubitemid 26041525)
128. Inhibition of PKA attenuates memory deficits induced by beta-amyloid (1-42), and decreases oxidative stress and NF-kappaB transcription factors. Eftekharzadeh B, Ramin M, Khodagholi F, Moradi S, Tabrizian K, Sharif R, Azami K, Beyer C, Sharifzadeh M, Behav Brain Res 2012 226 301 308 10.1016/j.bbr.2011. 08.015 21856333
129. HGF suppresses high glucose-mediated oxidative stress in mesangial cells by activation of PKG and inhibition of PKA. Hui L, Hong Y, Jingjing Z, Yuan H, Qi C, Nong Z, Free Radic Biol Med 2010 49 467 473 10.1016/j.freeradbiomed.2010. 05.002 20466058
130. Gene microarrays in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. Blalock EM, Chen KC, Sharrow K, Herman JP, Porter NM, Foster TC, Landfield PW, J Neurosci 2003 23 3807 3819 12736351 (Pubitemid 36958487)
131. Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner. Buxbaum JD, Ruefli AA, Parker CA, Cypess AM, Greengard P, Proc Natl Acad Sci U S A 1994 91 4489 4493 10.1073/pnas.91.10.4489 8183935 (Pubitemid 24143459)
132. Calcium ionophore increases amyloid beta peptide production by cultured cells. Querfurth HW, Selkoe DJ, Biochemistry 1994 33 4550 4561 10.1021/bi00181a016 8161510 (Pubitemid 24145103)
133. Caffeine stimulates amyloid beta-peptide release from beta-amyloid precursor protein-transfected HEK293 cells. Querfurth HW, Jiang J, Geiger JD, Selkoe DJ, J Neurochem 1997 69 1580 1591 9326287 (Pubitemid 27406959)
134. Dantrolene ameliorates cognitive decline and neuropathology in Alzheimer triple transgenic mice. Peng J, Liang G, Inan S, Wu Z, Joseph DJ, Meng Q, Peng Y, Eckenhoff MF, Wei H, Neurosci Lett 2012 516 274 279 10.1016/j.neulet.2012.04. 008 22516463
135. Stabilizing ER Ca2+ channel function as an early preventative strategy for Alzheimer's disease. Chakroborty S, Briggs C, Miller MB, Goussakov I, Schneider C, Kim J, Wicks J, Richardson JC, Conklin V, Cameransi BG, Stutzmann GE, PLoS One 2012 7 52056 10.1371/journal.pone.0052056 23284867
136. Dantrolene protects neurons against kainic acid induced apoptosis in vitro and in vivo. Popescu BO, Oprica M, Sajin M, Stanciu CL, Bajenaru O, Predescu A, Vidulescu C, Popescu LM, J Cell Mol Med 2002 6 555 569 10.1111/j.1582-4934.2002.tb00454.x 12611640 (Pubitemid 44146434)
137. Dantrolene is cytoprotective in two models of neuronal cell death. Wei H, Perry DC, J Neurochem 1996 67 2390 2398 8931471 (Pubitemid 26392509)
138. Effects of dantrolene on extracellular glutamate concentration and neuronal death in the rat hippocampal CA1 region subjected to transient ischemia. Nakayama R, Yano T, Ushijima K, Abe E, Terasaki H, Anesthesiology 2002 96 705 710 10.1097/00000542-200203000-00029 11873048 (Pubitemid 34193513)
139. Dantrolene is neuroprotective in Huntington's disease transgenic mouse model. Chen X, Wu J, Lvovskaya S, Herndon E, Supnet C, Bezprozvanny I, Mol Neurodegener 2011 6 81 10.1186/1750-1326-6-81 22118545
140. Calcium leak through ryanodine receptor is involved in neuronal death induced by mutant huntingtin. Suzuki M, Nagai Y, Wada K, Koike T, Biochem Biophys Res Commun 2012 429 18 23 10.1016/j.bbrc.2012.10.107 23131566
141. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. Chen X, Tang TS, Tu H, Nelson O, Pook M, Hammer R, Nukina N, Bezprozvanny I, J Neurosci 2008 28 12713 12724 10.1523/JNEUROSCI.3909-08.2008 19036964
142. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. Liu J, Tang TS, Tu H, Nelson O, Herndon E, Huynh DP, Pulst SM, Bezprozvanny I, J Neurosci 2009 29 9148 9162 10.1523/JNEUROSCI.0660-09.2009 19625506
143. Dantrolene prevents glutamate cytotoxicity and Ca2+ release from intracellular stores in cultured cerebral cortical neurons. Frandsen A, Schousboe A, J Neurochem 1991 56 1075 1078 10.1111/j.1471-4159.1991.tb02031.x 1671584 (Pubitemid 21922725)
144. Glutamate receptor activation in cultured cerebellar granule cells increases cytosolic free Ca2+ by mobilization of cellular Ca2+ and activation of Ca2+ influx. Bouchelouche P, Belhage B, Frandsen A, Drejer J, Schousboe A, Exp Brain Res 1989 76 281 291 2569984 (Pubitemid 19180455)
145. Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: involvement of calcium and oxyradicals. Guo Q, Sopher BL, Furukawa K, Pham DG, Robinson N, Martin GM, Mattson MP, J Neurosci 1997 17 4212 4222 9151738 (Pubitemid 27220612)
146. The cell death-promoting gene DP5, which interacts with the BCL2 family, is induced during neuronal apoptosis following exposure to amyloid beta protein. Imaizumi K, Morihara T, Mori Y, Katayama T, Tsuda M, Furuyama T, Wanaka A, Takeda M, Tohyama M, J Biol Chem 1999 274 7975 7981 10.1074/jbc.274.12.7975 10075695 (Pubitemid 29144268)
147. Up-regulation of the type 3 ryanodine receptor is neuroprotective in the TgCRND8 mouse model of Alzheimer's disease. Supnet C, Noonan C, Richard K, Bradley J, Mayne M, J Neurochem 2010 112 356 365 10.1111/j.1471-4159.2009.06487. x 19903243
148. Calcium signaling in neurons: molecular mechanisms and cellular consequences. Ghosh A, Greenberg ME, Science 1995 268 239 247 10.1126/science.7716515 7716515
149. Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. Trinchese F, Fa M, Liu S, Zhang H, Hidalgo A, Schmidt SD, Yamaguchi H, Yoshii N, Mathews PM, Nixon RA, Arancio O, J Clin Invest 2008 118 2796 2807 10.1172/JCI34254 18596919
150. Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease. Grynspan F, Griffin WR, Cataldo A, Katayama S, Nixon RA, Brain Res 1997 763 145 158 10.1016/S0006-8993(97)00384-3 9296555 (Pubitemid 27364434)
151. Ca2 + -induced apoptosis through calcineurin dephosphorylation of BAD. Wang HG, Pathan N, Ethell IM, Krajewski S, Yamaguchi Y, Shibasaki F, McKeon F, Bobo T, Franke TF, Reed JC, Science 1999 284 339 343 10.1126/science.284.5412. 339 10195903
152. Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. Dineley KT, Hogan D, Zhang WR, Taglialatela G, Neurobiol Learn Mem 2007 88 217 224 10.1016/j.nlm.2007.03.010 17521929 (Pubitemid 47223751)
153. The role of calcineurin in amyloid-beta-peptides-mediated cell death. Cardoso SM, Oliveira CR, Brain Res 2005 1050 1 7 10.1016/j.brainres.2005.04.078 15975561 (Pubitemid 40922711)
154. LTP and LTD: an embarrassment of riches. Malenka RC, Bear MF, Neuron 2004 44 5 21 10.1016/j.neuron.2004.09.012 15450156 (Pubitemid 39348827)
155. The role of the endoplasmic reticulum Ca2+ store in the plasticity of central neurons. Bardo S, Cavazzini MG, Emptage N, Trends Pharmacol Sci 2006 27 78 84 10.1016/j.tips.2005.12.008 16412523 (Pubitemid 43184028)
156. Presence and functional significance of presynaptic ryanodine receptors. Bouchard R, Pattarini R, Geiger JD, Prog Neurobiol 2003 69 391 418 10.1016/S0301-0082(03)00053-4 12880633 (Pubitemid 36869008)
157. Short-term synaptic plasticity. Zucker RS, Regehr WG, Annu Rev Physiol 2002 64 355 405 10.1146/annurev.physiol.64.092501.114547 11826273 (Pubitemid 34259234)
158. From form to function: calcium compartmentalization in dendritic spines. Yuste R, Majewska A, Holthoff K, Nat Neurosci 2000 3 653 659 10.1038/76609 10862697 (Pubitemid 30437199)
159. Spatial segregation of neuronal calcium signals encodes different forms of LTP in rat hippocampus. Raymond CR, Redman SJ, J Physiol 2006 570 97 111 10.1113/jphysiol.2005.098947 16284072
160. Dantrolene-Na (Dantrium) blocks induction of long-term potentiation in hippocampal slices. Obenaus A, Mody I, Baimbridge KG, Neurosci Lett 1989 98 172 178 10.1016/0304-3940(89)90505-3 2710411 (Pubitemid 19077393)
161. Thapsigargin blocks the induction of long-term potentiation in rat hippocampal slices. Harvey J, Collingridge GL, Neurosci Lett 1992 139 197 200 10.1016/0304-3940(92)90551-H 1319014
162. Calcium stores regulate the polarity and input specificity of synaptic modification. Nishiyama M, Hong K, Mikoshiba K, Poo MM, Kato K, Nature 2000 408 584 588 10.1038/35046067 11117745
163. Calcium stores and synaptic plasticity. Fitzjohn SM, Collingridge GL, Cell Calcium 2002 32 405 411 10.1016/S0143416002001999 12543099 (Pubitemid 36175760)
164. Postsynaptic modulation of AMPA receptor-mediated synaptic responses and LTP by the type 3 ryanodine receptor. Shimuta M, Yoshikawa M, Fukaya M, Watanabe M, Takeshima H, Manabe T, Mol Cell Neurosci 2001 17 921 930 10.1006/mcne.2001.0981 11358488 (Pubitemid 32510539)
165. Facilitation of NMDAR-independent LTP and spatial learning in mutant mice lacking ryanodine receptor type 3. Futatsugi A, Kato K, Ogura H, Li ST, Nagata E, Kuwajima G, Tanaka K, Itohara S, Mikoshiba K, Neuron 1999 24 701 713 10.1016/S0896-6273(00)81123-X 10595520
166. Ca2+ signaling in mouse cortical neurons studied by two-photon imaging and photoreleased inositol triphosphate. Stutzmann GE, LaFerla FM, Parker I, J Neurosci 2003 23 758 765 12574404 (Pubitemid 36206166)
167. Early calcium dysregulation in Alzheimer's disease: setting the stage for synaptic dysfunction. Chakroborty S, Stutzmann GE, Sci China Life Sci 2011 54 752 762 10.1007/s11427-011-4205-7 21786198
168. Early presynaptic and postsynaptic calcium signaling abnormalities mask underlying synaptic depression in presymptomatic Alzheimer's disease mice. Chakroborty S, Kim J, Schneider C, Jacobson C, Molgo J, Stutzmann GE, J Neurosci 2012 32 8341 8353 10.1523/JNEUROSCI.0936-12.2012 22699914
169. Ryanodine receptor-2 upregulation and nicotine-mediated plasticity. Ziviani E, Lippi G, Bano D, Munarriz E, Guiducci S, Zoli M, Young KW, Nicotera P, EMBO J 2011 30 194 204 10.1038/emboj.2010.279 21113126
170. Spatial learning induced changes in expression of the ryanodine type II receptor in the rat hippocampus. Zhao W, Meiri N, Xu H, Cavallaro S, Quattrone A, Zhang L, Alkon DL, FASEB J 2000 14 290 300 10657985 (Pubitemid 30086066)
171. Comprehensive behavioral phenotyping of ryanodine receptor type 3 (RyR3) knockout mice: decreased social contact duration in two social interaction tests. Matsuo N, Tanda K, Nakanishi K, Yamasaki N, Toyama K, Takao K, Takeshima H, Miyakawa T, Front Behav Neurosci 2009 3 3 19503748
172. Time domains of neuronal Ca2+ signaling and associative memory: steps through a calexcitin, ryanodine receptor, K + channel cascade. Alkon DL, Nelson TJ, Zhao W, Cavallaro S, Trends Neurosci 1998 21 529 537 10.1016/S0166-2236(98) 01277-6 9881851 (Pubitemid 28555695)
173. Differential trafficking of AMPA and NMDA receptors by SAP102 and PSD-95 underlies synapse development. Elias GM, Elias LA, Apostolides PF, Kriegstein AR, Nicoll RA, Proc Natl Acad Sci U S A 2008 105 20953 20958 10.1073/pnas.0811025106 19104036
174. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Tollefson GD, Biol Psychiatry 1990 27 1133 1142 10.1016/0006-3223(90)90050-C 2187540 (Pubitemid 20150025)
175. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date. Bullock R, Alzheimer Dis Assoc Disord 2006 20 23 29 10.1097/01.wad.0000201847.29836.a5 16493232 (Pubitemid 44356890)